6K9 Stock Chart & Stats
€0.30
€0.03(5.70%)
At close: 4:00 PM EDT
€0.30
€0.03(5.70%)
Day’s Range― - ―
52-Week Range€0.21 - €3.12
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€26.38M
Enterprise Value€9.98M
Total Cash (Recent Filing)€42.99M
Total Debt (Recent Filing)€244.99K
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Nov 11, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding91,879,170
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.85Price Target Upside849.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low leverage reduces fixed financial obligations and preserves flexibility while the company advances its pipeline. Unlike a highly indebted developer, CNTX is not using substantial debt to fund operations, which limits interest-related pressure and balance-sheet risk.
Pipeline AdvancementProgress across two T cell engager programs provides multiple development opportunities rather than reliance on a single candidate. Planned milestones through 2027 could create durable clinical inflection points and support broader validation of CNTX’s solid-tumor strategy.
Differentiated TCE StrategyA focus on selective, conditionally active T cell engagers may help differentiate CNTX’s approach in solid tumors, where safety and tumor-microenvironment challenges are important. Potentially improving tolerability could support combination use and expansion into earlier treatment lines.
Bears Say
Pre-Revenue Business ModelCNTX has no commercial product revenue to offset research and operating costs, so its financial profile remains dependent on advancing development assets. Until a program reaches commercialization or a strategic transaction generates proceeds, operating performance will remain disconnected from sales growth.
Widening Net LossesThe widening loss trajectory indicates that development spending is increasing faster than any offsetting income because the pipeline remains pre-commercial. Persistent losses reduce retained capital and make future progress increasingly dependent on successful clinical execution and continued access to funding.
Accelerating Cash BurnIncreasing operating and free-cash-flow deficits show that CNTX is consuming more cash as it develops its programs. Sustained burn can shorten financial runway, constrain the pace of clinical investment, and increase pressure to secure additional capital or strategic support.
Context Therapeutics News
6K9 FAQ
What was Context Therapeutics’s price range in the past 12 months?
Context Therapeutics lowest stock price was €0.21 and its highest was €3.12 in the past 12 months.
What is Context Therapeutics’s market cap?
Context Therapeutics’s market cap is €26.38M.
When is Context Therapeutics’s upcoming earnings report date?
Context Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 34 days.
How were Context Therapeutics’s earnings last quarter?
Context Therapeutics released its earnings results on Aug 05, 2026. The company reported -€0.134 earnings per share for the quarter, missing the consensus estimate of -€0.082 by -€0.052.
Is Context Therapeutics overvalued?
According to Wall Street analysts Context Therapeutics’s price is currently Undervalued.
Does Context Therapeutics pay dividends?
Context Therapeutics does not currently pay dividends.
What is Context Therapeutics’s EPS estimate?
Context Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Context Therapeutics have?
Context Therapeutics has 91,879,170 shares outstanding.
What happened to Context Therapeutics’s price movement after its last earnings report?
Context Therapeutics reported an EPS of -€0.134 in its last earnings report, missing expectations of -€0.082. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Context Therapeutics?
Currently, no hedge funds are holding shares in DE:6K9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
6K9 Stock 12 Month Forecast
Average Price Target
€2.85
▲(849.73% Upside)